Hawaii Biotech,

Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Current vaccine candidates in clinical or pre-clinical development target the West Nile virus, Tick borne flaviviruses, Zika virus, Crimean-Congo hemorrhagic fever virus, and Chikungunya virus. HBI’s drug development activities are focused on small molecule drugs that block intracellular and extracellural bacterial toxins. Product opportunities include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company also partners its proprietary saponin adjuvant for vaccine development.